With an investment in the high double-digit million-euro range, BASF is strengthening its portfolio of biological innovations.
The products manufactured at the plant include biological fungicides and biological seed treatment, giving farmers access to innovative solutions to support sustainable, integrated crop protection programs.
The BioHub uses microorganisms to convert renewable raw materials such as glucose into the desired products – a process known as fermentation.
The production of key biological active ingredients successfully began this year, including the bacterium Bacillus amyloliquefaciens, which forms the basis of the biological fungicide Serifel, and the main building block of Inscalis, a novel insecticide based on the fungal strain Penicillium coprobium.
Bringing this production process in-house strengthens BASF’s execution excellence, increases flexibility, and enhances the resilience of supply chains.
Dr Melanie Bausen-Wiens, Agricultural Solutions director in charge of technology says the successful commissioning of the BioHub marks an important step forward in industrial biotechnology.
“By bringing fermentation production in-house, we directly link our expertise in research with industrial-scale manufacturing, allowing us to accelerate and adapt biotechnological innovations,” she adds.
Business director Maximilian Becker says the global market for biological crop protection solutions continues to grow steadily.
“With this new fermentation plant, we have established a scalable and flexible platform that enables us to strengthen our biosolutions portfolio while ensuring a consistent and dependable supply for our customers,” he says.
